Literature DB >> 18558711

Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.

M Jeyakumar1, Paul Webb, John D Baxter, Thomas S Scanlan, John A Katzenellenbogen.   

Abstract

The potency and efficacy of ligands for nuclear receptors (NR) result both from the affinity of the ligand for the receptor and from the affinity that various coregulatory proteins have for ligand-receptor complexes; the latter interaction, however, is rarely quantified. To understand the molecular basis for ligand potency and efficacy, we developed dual time-resolved fluorescence resonance energy transfer (tr-FRET) assays and quantified binding of both ligand and coactivator or corepressor to the thyroid hormone receptor (TR). Promoter-bound TR exerts dual transcriptional regulatory functions, recruiting corepressor proteins and repressing transcription in the absence of thyroid hormones (THs) and shedding corepressors in favor of coactivators upon binding agonists, activating transcription. Our tr-FRET assays involve a TRE sequence labeled with terbium (fluorescence donor), TRbeta.RXRalpha heterodimer, and fluorescein-labeled NR interaction domains of coactivator SRC3 or corepressor NCoR (fluorescence acceptors). Through coregulator titrations, we could determine the affinity of SRC3 or NCoR for TRE-bound TR.RXR heterodimers, unliganded or saturated with different THs. Alternatively, through ligand titrations, we could determine the relative potencies of different THs. The order of TR agonist potencies is as follows: GC-1 approximately T 3 approximately TRIAC approximately T 4 >> rT 3 (for both coactivator recruitment and corepressor dissociation); the affinities of SRC3 binding to TR-ligand complexes followed a similar trend. This highlights the fact that the low activity of rT 3 is derived both from its low affinity for TR and from the low affinity of SRC for the TR-rT 3 complex. The TR antagonist NH-3 failed to induce SRC3 recruitment but did effect NCoR dissociation. These assays provide quantitative information about the affinity of two key interactions that are determinants of NR ligand potency and efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558711      PMCID: PMC2574600          DOI: 10.1021/bi800393u

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  51 in total

1.  Site-specific fluorescent labeling of estrogen receptors and structure-activity relationships of ligands in terms of receptor dimer stability.

Authors:  Anobel Tamrazi; John A Katzenellenbogen
Journal:  Methods Enzymol       Date:  2003       Impact factor: 1.600

2.  Rational design and synthesis of a novel thyroid hormone antagonist that blocks coactivator recruitment.

Authors:  Ngoc-Ha Nguyen; James W Apriletti; Suzana T Cunha Lima; Paul Webb; John D Baxter; Thomas S Scanlan
Journal:  J Med Chem       Date:  2002-07-18       Impact factor: 7.446

Review 3.  Thyroid hormone action at the cellular, genomic and target gene levels.

Authors:  Paul M Yen; Shinichiro Ando; Xu Feng; Ying Liu; Padma Maruvada; Xianmin Xia
Journal:  Mol Cell Endocrinol       Date:  2006-01-25       Impact factor: 4.102

4.  The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay.

Authors:  Mary Szatkowski Ozers; Bryan D Marks; Krishne Gowda; Kevin R Kupcho; Kerry M Ervin; Therese De Rosier; Naveeda Qadir; Hildegard C Eliason; Steven M Riddle; Mohammed Saleh Shekhani
Journal:  Biochemistry       Date:  2007-01-23       Impact factor: 3.162

5.  Simultaneous monitoring of discrete binding events using dual-acceptor terbium-based LRET.

Authors:  Kevin R Kupcho; Deborah K Stafslien; Therese DeRosier; Tina M Hallis; Mary Szatkowski Ozers; Kurt W Vogel
Journal:  J Am Chem Soc       Date:  2007-10-11       Impact factor: 15.419

Review 6.  Mechanisms of thyroid hormone action: insights from X-ray crystallographic and functional studies.

Authors:  R C Ribeiro; J W Apriletti; R L Wagner; B L West; W Feng; R Huber; P J Kushner; S Nilsson; T Scanlan; R J Fletterick; F Schaufele; J D Baxter
Journal:  Recent Prog Horm Res       Date:  1998

7.  Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor.

Authors:  M Jeyakumar; M R Tanen; M K Bagchi
Journal:  Mol Endocrinol       Date:  1997-06

8.  Influence of a steroid receptor DNA-binding domain on transcriptional regulatory functions.

Authors:  J A Lefstin; J R Thomas; K R Yamamoto
Journal:  Genes Dev       Date:  1994-12-01       Impact factor: 11.361

9.  A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor.

Authors:  X Zhang; M Jeyakumar; S Petukhov; M K Bagchi
Journal:  Mol Endocrinol       Date:  1998-04

10.  Thyroid hormone response element organization dictates the composition of active receptor.

Authors:  Lara F R Velasco; Marie Togashi; Paul G Walfish; Rutinéia P Pessanha; Fanny N Moura; Gustavo B Barra; Phuong Nguyen; Rachelle Rebong; Chaoshen Yuan; Luiz A Simeoni; Ralff C J Ribeiro; John D Baxter; Paul Webb; Francisco A R Neves
Journal:  J Biol Chem       Date:  2007-02-20       Impact factor: 5.157

View more
  17 in total

Review 1.  Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses.

Authors:  Laura N Vandenberg; Theo Colborn; Tyrone B Hayes; Jerrold J Heindel; David R Jacobs; Duk-Hee Lee; Toshi Shioda; Ana M Soto; Frederick S vom Saal; Wade V Welshons; R Thomas Zoeller; John Peterson Myers
Journal:  Endocr Rev       Date:  2012-03-14       Impact factor: 19.871

2.  Structure of a thyroid hormone receptor DNA-binding domain homodimer bound to an inverted palindrome DNA response element.

Authors:  Yi Chen; Matthew A Young
Journal:  Mol Endocrinol       Date:  2010-07-07

3.  Exploration of dimensions of estrogen potency: parsing ligand binding and coactivator binding affinities.

Authors:  M Jeyakumar; Kathryn E Carlson; Jillian R Gunther; John A Katzenellenbogen
Journal:  J Biol Chem       Date:  2011-02-14       Impact factor: 5.157

4.  Structural basis for negative cooperativity within agonist-bound TR:RXR heterodimers.

Authors:  Balananda-Dhurjati K Putcha; Edward Wright; Joseph S Brunzelle; Elias J Fernandez
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-02       Impact factor: 11.205

Review 5.  Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention.

Authors:  Donato F Romagnolo; Janos Zempleni; Ornella I Selmin
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

6.  Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens.

Authors:  Yan Jiang; Ping Gong; Zeynep Madak-Erdogan; Teresa Martin; Muthu Jeyakumar; Kathryn Carlson; Ikhlas Khan; Troy J Smillie; Amar G Chittiboyina; Sateesh C K Rotte; William G Helferich; John A Katzenellenbogen; Benita S Katzenellenbogen
Journal:  FASEB J       Date:  2013-07-23       Impact factor: 5.191

7.  Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands.

Authors:  Vincent M Carroll; M Jeyakumar; Kathryn E Carlson; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2011-12-14       Impact factor: 7.446

Review 8.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

Authors:  Terry W Moore; Christopher G Mayne; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-20

9.  Development of time resolved fluorescence resonance energy transfer-based assay for FXR antagonist discovery.

Authors:  Donna D Yu; Wenwei Lin; Taosheng Chen; Barry M Forman
Journal:  Bioorg Med Chem       Date:  2013-05-07       Impact factor: 3.641

10.  Non-monotonic dose responses in studies of endocrine disrupting chemicals: bisphenol a as a case study.

Authors:  Laura N Vandenberg
Journal:  Dose Response       Date:  2013-10-07       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.